Summary & Overview
HCPCS C1734: Implantable Orthopedic/Device/Drug Matrix for Bone or Soft Tissue
HCPCS Level II code C1734 describes an implantable orthopedic/device/drug matrix used to support opposing bone-to-bone or soft tissue-to-bone repair. This code captures implantable scaffold or matrix products that may include drug delivery components and are placed during surgical procedures. Its national relevance stems from growing use of combination device/drug matrices in orthopedic and reconstructive procedures, with implications for coding consistency, coverage determination, and hospital/surgical reimbursement.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and how the code is positioned within payer policy frameworks. The publication summarizes common billing modifiers associated with implantable device procedures, highlights where data is available or not, and outlines what to look for in payer medical policy and coverage criteria.
This resource is intended for billing and coding professionals, hospital revenue staff, and clinicians involved in surgical implant selection. It provides practical benchmarks, policy considerations, and pointers on clinical documentation necessary to support claims for implantable orthopedic/device/drug matrices coded with C1734.
Billing Code Overview
HCPCS Level II code C1734 describes an implantable orthopedic/device/drug matrix designed for opposing bone-to-bone or soft tissue-to-bone applications. This entry represents a surgically implanted matrix used to support bone or soft-tissue repair where an implantable scaffold or drug-eluting matrix is indicated.
-
Service type: Implantable orthopedic/device/drug matrix
-
Typical site of service: Inpatient or outpatient surgical settings, including hospital operating rooms and ambulatory surgical centers
Clinical & Coding Specifications
Clinical Context
A 58-year-old male presents with progressive medial knee joint pain and radiographic evidence of advanced focal tibiofemoral cartilage loss with bone-to-bone contact after prior conservative management. Surgical planning identifies the need for an implantable orthopedic/device/drug matrix designed to oppose bone-to-bone or soft tissue-to-bone contact to restore joint congruity and provide a biologic scaffold for healing. The procedure is performed in an ambulatory surgery center under general anesthesia with possible regional block; intraoperative steps include exposure of the affected compartment, debridement of unstable cartilage and osteophytes, sizing and implantation of the matrix device into the defect, fixation as required, and layered wound closure. Typical intraoperative documentation includes device model and implant lot number, indication for implant placement, size and location of the defect, estimated blood loss, anesthesia type, and any intraoperative complications. Postoperative workflow includes recovery in PACU, pain control, discharge instructions with weight-bearing status, physical therapy referral, and device-specific follow-up for wound check and radiographic evaluation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the orthopedic implant procedure requires substantially greater work than typical due to complexity (document rationale and time). |